Qualigen Therapeutics Inc (QLGN)

$1.88 -0.02 (-1.05%)
Market Cap 3.22M
Revenue (ttm) 0.00
Net Income (ttm) -6.26M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio -0.08
Volume 20,300
Avg Vol 1,053,216
Day's Range N/A - N/A
Shares Out 1.70M
Stochastic %K 57%
Beta -0.17
Analysts Strong Buy
Price Target $200.00

Company Profile

Qualigen Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development of treatments for adult and pediatric cancer. The company's lead program is QN-302, an investigational small molecule G-quadruplexes (G4)-selective transcription inhibitor, which is in Phase I clinical trial for the treatment of pancreatic cancer and other solid tumors. It is also developing Pan-RAS that is in preclinical stage for the treatment of advanced solid tumors. The company was founded in 1996...

Industry: Biotechnology
Sector: Healthcare
Phone: 760 452 8111
Website: qlgntx.com
Address:
5857 Owens Avenue, Suite 300, Carlsbad, United States
LibbyJackson
LibbyJackson Aug. 20 at 1:29 PM
$QLGN The consolidation in that channel is perfect for a strong rally in August. @LibbyJackson
0 · Reply
FeliciaMath
FeliciaMath Aug. 18 at 6:58 PM
bought $QLGN at 1.96
1 · Reply
Trader11112
Trader11112 Aug. 14 at 8:23 PM
$QLGN when eua?
0 · Reply
ProGainer
ProGainer Aug. 13 at 3:32 PM
$QLGN accelerating to the end
0 · Reply
ProGainer
ProGainer Aug. 13 at 2:33 PM
$QLGN Zero here we come! This share is a disaster....
0 · Reply
ProGainer
ProGainer Aug. 12 at 3:07 AM
$QLGN It's accelerating to $0. 2025 could be the end.
0 · Reply
ProGainer
ProGainer Aug. 11 at 1:00 PM
$QLGN What's the target? $0
0 · Reply
LeahJennings
LeahJennings Aug. 10 at 5:37 PM
$QLGN Follow the price target.
0 · Reply
AmeliaRobson
AmeliaRobson Aug. 10 at 2:33 PM
$QLGN Follow the price target.
0 · Reply
nUme22
nUme22 Aug. 5 at 4:43 PM
$QLGN RS and then dilution.. and then new pump to draw new suckers.. and then the slow gradual dump.. The cycle continues
2 · Reply
Latest News on QLGN
Qualigen Therapeutics Announces $4.5 Million Private Placement of Series A-3 Convertible Preferred Stock

Jul 28, 2025, 12:41 PM EDT - 23 days ago

Qualigen Therapeutics Announces $4.5 Million Private Placement of Series A-3 Convertible Preferred Stock

Qualigen Therapeutics, Inc. receives expected notification of deficiency from Nasdaq related to delayed filing of quarterly report on Form 10-Q

May 19, 2025, 5:25 PM EDT - 3 months ago

Qualigen Therapeutics, Inc. receives expected notification of deficiency from Nasdaq related to delayed filing of quarterly report on Form 10-Q

Qualigen Therapeutics, Inc. Receives Notification of Deficiency from Nasdaq Related to Delayed Filing of Annual Report on Form 10-K

May 1, 2025, 4:20 PM EDT - 3 months ago

Qualigen Therapeutics, Inc. Receives Notification of Deficiency from Nasdaq Related to Delayed Filing of Annual Report on Form 10-K

Univest Securities, LLC Announces Successful Closing of $5.1 Million Private Placement for Qualigen Therapeutics, Inc. (NASDAQ: QLGN)

Nov 25, 2024, 5:00 PM EST - 9 months ago

Univest Securities, LLC Announces Successful Closing of $5.1 Million Private Placement for Qualigen Therapeutics, Inc. (NASDAQ: QLGN)

Shares Expected to Begin Trading on Split-Adjusted Basis on November 5, 2024

Nov 1, 2024, 9:00 AM EDT - 10 months ago

Shares Expected to Begin Trading on Split-Adjusted Basis on November 5, 2024

Qualigen Therapeutics, Inc. Announces management changes.

Sep 26, 2024, 5:10 PM EDT - 11 months ago

Qualigen Therapeutics, Inc. Announces management changes.

Qualigen Therapeutics, Inc. Received Extension from Nasdaq Hearings Panel

Sep 20, 2024, 9:00 AM EDT - 11 months ago

Qualigen Therapeutics, Inc. Received Extension from Nasdaq Hearings Panel

Univest Securities, LLC Announces Closing of $3.46 Million Registered Direct Offering for its Client Qualigen Therapeutics, Inc. (NASDAQ: QLGN)

Sep 6, 2024, 5:00 PM EDT - 1 year ago

Univest Securities, LLC Announces Closing of $3.46 Million Registered Direct Offering for its Client Qualigen Therapeutics, Inc. (NASDAQ: QLGN)

Qualigen Therapeutics, Inc. Announces Closing of $3.47 Million Public Offering

Sep 6, 2024, 4:30 PM EDT - 1 year ago

Qualigen Therapeutics, Inc. Announces Closing of $3.47 Million Public Offering

Qualigen Therapeutics, Inc. Announces Pricing of $3.46 Million Public Offering

Sep 5, 2024, 9:00 AM EDT - 1 year ago

Qualigen Therapeutics, Inc. Announces Pricing of $3.46 Million Public Offering

Qualigen Therapeutics, Inc. Received Nasdaq Notice of a Delisting Determination

May 30, 2024, 4:00 PM EDT - 1 year ago

Qualigen Therapeutics, Inc. Received Nasdaq Notice of a Delisting Determination

Qualigen Therapeutics' Novel Direct Pan-RAS Inhibitors Presented at American Association of Cancer Research (AACR) 2024 Annual Meeting

Apr 10, 2024, 8:00 AM EDT - 1 year ago

Qualigen Therapeutics' Novel Direct Pan-RAS Inhibitors Presented at American Association of Cancer Research (AACR) 2024 Annual Meeting

Qualigen Therapeutics Announces Poster Featuring Positive Early Clinical Experience with QN-302, a Novel First-in-Class G-Quadruplex Experimental Anti-Cancer Drug, at the American Association of Cancer Research (AACR) 2024 Annual Meeting

Apr 9, 2024, 8:00 AM EDT - 1 year ago

Qualigen Therapeutics Announces Poster Featuring Positive Early Clinical Experience with QN-302, a Novel First-in-Class G-Quadruplex Experimental Anti-Cancer Drug, at the American Association of Cancer Research (AACR) 2024 Annual Meeting

Qualigen Therapeutics Provides Corporate Update for Third Quarter and To Date 2023

Nov 14, 2023, 4:30 PM EST - 1 year ago

Qualigen Therapeutics Provides Corporate Update for Third Quarter and To Date 2023

Qualigen Therapeutics Announces First Patient Dosed in the Phase 1a Clinical Trial of QN-302 for Treatment of Advanced or Metastatic Solid Tumors

Nov 7, 2023, 8:30 AM EST - 1 year ago

Qualigen Therapeutics Announces First Patient Dosed in the Phase 1a Clinical Trial of QN-302 for Treatment of Advanced or Metastatic Solid Tumors

Poster Highlighting Qualigen Therapeutics' Pan-RAS Inhibitor Platform Presented at AACR Special Conference: Advances in Breast Cancer

Oct 23, 2023, 8:30 AM EDT - 1 year ago

Poster Highlighting Qualigen Therapeutics' Pan-RAS Inhibitor Platform Presented at AACR Special Conference: Advances in Breast Cancer

Qualigen Therapeutics Presents Scientific Data on QN-302 at AACR Special Conference: Pancreatic Cancer 2023

Sep 27, 2023, 8:30 AM EDT - 2 years ago

Qualigen Therapeutics Presents Scientific Data on QN-302 at AACR Special Conference: Pancreatic Cancer 2023

Qualigen Therapeutics Partners with TD2 for Phase 1 Clinical Development of QN-302 for the Treatment of Advanced or Metastatic Solid Tumors

Aug 17, 2023, 8:30 AM EDT - 2 years ago

Qualigen Therapeutics Partners with TD2 for Phase 1 Clinical Development of QN-302 for the Treatment of Advanced or Metastatic Solid Tumors

Qualigen Therapeutics, Inc. Reports Financial Results and Corporate Update for Quarter Ending June 30, 2023

Aug 15, 2023, 8:30 AM EDT - 2 years ago

Qualigen Therapeutics, Inc. Reports Financial Results and Corporate Update for Quarter Ending June 30, 2023

Qualigen Therapeutics Announces US FDA IND Clearance to Initiate Phase 1 Clinical Trial of QN-302 for Treatment of Advanced or Metastatic Solid Tumors

Aug 1, 2023, 8:30 AM EDT - 2 years ago

Qualigen Therapeutics Announces US FDA IND Clearance to Initiate Phase 1 Clinical Trial of QN-302 for Treatment of Advanced or Metastatic Solid Tumors

Qualigen Therapeutics Divests FastPack® Diagnostics Business

Jul 24, 2023, 8:15 AM EDT - 2 years ago

Qualigen Therapeutics Divests FastPack® Diagnostics Business

Poster Highlighting Qualigen Therapeutics' Pan-RAS Inhibitor Platform Presented at American Society of Clinical Oncology (ASCO) 2023 Annual Meeting

Jun 5, 2023, 8:15 AM EDT - 2 years ago

Poster Highlighting Qualigen Therapeutics' Pan-RAS Inhibitor Platform Presented at American Society of Clinical Oncology (ASCO) 2023 Annual Meeting

Qualigen Therapeutics, Inc. Reports Fourth Quarter and Year-End 2022 Financial Results and Provides Corporate Update

May 2, 2023, 4:30 PM EDT - 2 years ago

Qualigen Therapeutics, Inc. Reports Fourth Quarter and Year-End 2022 Financial Results and Provides Corporate Update

Qualigen Therapeutics' Pan-RAS Inhibitor Program Highlighted in Two Abstracts at American Society of Clinical Oncology (ASCO) 2023 Annual Meeting

May 2, 2023, 8:15 AM EDT - 2 years ago

Qualigen Therapeutics' Pan-RAS Inhibitor Program Highlighted in Two Abstracts at American Society of Clinical Oncology (ASCO) 2023 Annual Meeting

Qualigen Therapeutics, Inc. Receives Nasdaq Notice Regarding Delayed Form 10-K Filing

Apr 21, 2023, 5:46 PM EDT - 2 years ago

Qualigen Therapeutics, Inc. Receives Nasdaq Notice Regarding Delayed Form 10-K Filing

Qualigen Therapeutics Announces Four Posters on QN-302 Presented at the American Association of Cancer Research (AACR) 2023 Annual Meeting in Orlando, FL

Apr 18, 2023, 8:45 AM EDT - 2 years ago

Qualigen Therapeutics Announces Four Posters on QN-302 Presented at the American Association of Cancer Research (AACR) 2023 Annual Meeting in Orlando, FL

Qualigen Therapeutics Presents Data On QN-247 in Triple Negative Breast Cancer at the American Association for Cancer Research (AACR) Annual Meeting in Orlando, FL

Apr 18, 2023, 7:30 AM EDT - 2 years ago

Qualigen Therapeutics Presents Data On QN-247 in Triple Negative Breast Cancer at the American Association for Cancer Research (AACR) Annual Meeting in Orlando, FL

Composition of Matter Patent for QN-302 Granted by United States Patent and Trademark Office

Mar 21, 2023, 8:35 AM EDT - 2 years ago

Composition of Matter Patent for QN-302 Granted by United States Patent and Trademark Office

Qualigen Therapeutics to Present Five Posters at the American Association for Cancer Research Annual Meeting 2023

Mar 15, 2023, 9:05 AM EDT - 2 years ago

Qualigen Therapeutics to Present Five Posters at the American Association for Cancer Research Annual Meeting 2023

Qualigen Therapeutics Presents Data on its RAS Inhibitor Program at the American Association for Cancer Research: Targeting RAS Conference

Mar 9, 2023, 8:30 AM EST - 2 years ago

Qualigen Therapeutics Presents Data on its RAS Inhibitor Program at the American Association for Cancer Research: Targeting RAS Conference

Data on Potential Biomarker for Qualigen Therapeutics' Lead Program QN-302 Published in Peer-Reviewed Journal Molecules

Mar 8, 2023, 8:05 AM EST - 2 years ago

Data on Potential Biomarker for Qualigen Therapeutics' Lead Program QN-302 Published in Peer-Reviewed Journal Molecules

Qualigen Therapeutics Chief Executive Officer Michael Poirier Provides Letter to Stockholders

Feb 1, 2023, 9:05 AM EST - 2 years ago

Qualigen Therapeutics Chief Executive Officer Michael Poirier Provides Letter to Stockholders

Qualigen Therapeutics Initiates Good Laboratory Practice (GLP) Toxicology Studies on QN-302

Jan 24, 2023, 9:00 AM EST - 2 years ago

Qualigen Therapeutics Initiates Good Laboratory Practice (GLP) Toxicology Studies on QN-302

Qualigen Therapeutics Promotes Benedict M. Abugan to Vice President, Head of Diagnostics and Corporate Communications

Jan 23, 2023, 9:02 AM EST - 2 years ago

Qualigen Therapeutics Promotes Benedict M. Abugan to Vice President, Head of Diagnostics and Corporate Communications

Qualigen Therapeutics Receives Orphan Drug Designation from the U.S. Food and Drug Administration for QN-302, a G-Quadruplex (G4) Transcription Inhibitor for the Intended Indication of Pancreatic Cancer

Jan 10, 2023, 9:00 AM EST - 2 years ago

Qualigen Therapeutics Receives Orphan Drug Designation from the U.S. Food and Drug Administration for QN-302, a G-Quadruplex (G4) Transcription Inhibitor for the Intended Indication of Pancreatic Cancer

Qualigen Therapeutics Provides Update on Developments at NanoSynex; Significant Progress Reported on Infectious Disease Diagnostic Platform

Jan 5, 2023, 9:00 AM EST - 2 years ago

Qualigen Therapeutics Provides Update on Developments at NanoSynex; Significant Progress Reported on Infectious Disease Diagnostic Platform

Qualigen Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Rule

Dec 12, 2022, 8:30 AM EST - 2 years ago

Qualigen Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Rule

Qualigen Therapeutics Announces Pre-IND Feedback from U.S. Food and Drug Administration Regarding QN-302 for the Treatment of G4-Targeted Advanced Solid Tumors

Dec 7, 2022, 9:10 AM EST - 2 years ago

Qualigen Therapeutics Announces Pre-IND Feedback from U.S. Food and Drug Administration Regarding QN-302 for the Treatment of G4-Targeted Advanced Solid Tumors

Qualigen Therapeutics, Inc. Announces 1-for-10 Reverse Stock Split

Nov 22, 2022, 9:00 AM EST - 2 years ago

Qualigen Therapeutics, Inc. Announces 1-for-10 Reverse Stock Split

Qualigen Therapeutics, Inc. Reports Third Quarter 2022 Financial Results and Provides Corporate Update

Nov 15, 2022, 7:30 AM EST - 3 years ago

Qualigen Therapeutics, Inc. Reports Third Quarter 2022 Financial Results and Provides Corporate Update

Qualigen Therapeutics Announces Two Posters of Its RAS-Targeted Inhibitor Program at the National Cancer Institute

Oct 19, 2022, 9:00 AM EDT - 3 years ago

Qualigen Therapeutics Announces Two Posters of Its RAS-Targeted Inhibitor Program at the National Cancer Institute

Qualigen Therapeutics to Present at LD Micro Main Event XV

Oct 18, 2022, 9:00 AM EDT - 3 years ago

Qualigen Therapeutics to Present at LD Micro Main Event XV

Qualigen Therapeutics Presents Data on QN-302 at AACR's Pancreatic Cancer Meeting

Sep 14, 2022, 5:02 PM EDT - 3 years ago

Qualigen Therapeutics Presents Data on QN-302 at AACR's Pancreatic Cancer Meeting

Qualigen Therapeutics Announces Formation and First Meeting of QN-302 Scientific Advisory Board

Aug 18, 2022, 9:15 AM EDT - 3 years ago

Qualigen Therapeutics Announces Formation and First Meeting of QN-302 Scientific Advisory Board

Qualigen Therapeutics, Inc. Reports Second Quarter 2022 Financial Results and Provides Corporate Update

Aug 16, 2022, 7:30 AM EDT - 3 years ago

Qualigen Therapeutics, Inc. Reports Second Quarter 2022 Financial Results and Provides Corporate Update

Qualigen Therapeutics Reports Positive QN-247 Readout in Triple Negative Breast Cancer in Vivo Model

Aug 1, 2022, 8:30 AM EDT - 3 years ago

Qualigen Therapeutics Reports Positive QN-247 Readout in Triple Negative Breast Cancer in Vivo Model

Qualigen Therapeutics Announces Partnership with Hande Sciences To Scale-Up Manufacturing To Support IND-Enabling Studies for QN-302

Jul 6, 2022, 9:00 AM EDT - 3 years ago

Qualigen Therapeutics Announces Partnership with Hande Sciences To Scale-Up Manufacturing To Support IND-Enabling Studies for QN-302

Qualigen Therapeutics to Present at BIO International Convention

Jun 14, 2022, 9:00 AM EDT - 3 years ago

Qualigen Therapeutics to Present at BIO International Convention

Qualigen Therapeutics Announces IND-Enabling Studies to Advance Lead Program QN-302 Toward Clinical Trials

Jun 7, 2022, 9:04 AM EDT - 3 years ago

Qualigen Therapeutics Announces IND-Enabling Studies to Advance Lead Program QN-302 Toward Clinical Trials

Qualigen Therapeutics Acquires Majority Stake in Infectious Disease Diagnostics Technology Company NanoSynex

Jun 2, 2022, 9:00 AM EDT - 3 years ago

Qualigen Therapeutics Acquires Majority Stake in Infectious Disease Diagnostics Technology Company NanoSynex

LibbyJackson
LibbyJackson Aug. 20 at 1:29 PM
$QLGN The consolidation in that channel is perfect for a strong rally in August. @LibbyJackson
0 · Reply
FeliciaMath
FeliciaMath Aug. 18 at 6:58 PM
bought $QLGN at 1.96
1 · Reply
Trader11112
Trader11112 Aug. 14 at 8:23 PM
$QLGN when eua?
0 · Reply
ProGainer
ProGainer Aug. 13 at 3:32 PM
$QLGN accelerating to the end
0 · Reply
ProGainer
ProGainer Aug. 13 at 2:33 PM
$QLGN Zero here we come! This share is a disaster....
0 · Reply
ProGainer
ProGainer Aug. 12 at 3:07 AM
$QLGN It's accelerating to $0. 2025 could be the end.
0 · Reply
ProGainer
ProGainer Aug. 11 at 1:00 PM
$QLGN What's the target? $0
0 · Reply
LeahJennings
LeahJennings Aug. 10 at 5:37 PM
$QLGN Follow the price target.
0 · Reply
AmeliaRobson
AmeliaRobson Aug. 10 at 2:33 PM
$QLGN Follow the price target.
0 · Reply
nUme22
nUme22 Aug. 5 at 4:43 PM
$QLGN RS and then dilution.. and then new pump to draw new suckers.. and then the slow gradual dump.. The cycle continues
2 · Reply
MajinTru
MajinTru Aug. 1 at 1:11 PM
$QLGN Count me in on this one...
0 · Reply
st_89
st_89 Jul. 29 at 3:17 PM
$QLGN tomorrow 🚀
0 · Reply
Triptrailz
Triptrailz Jul. 28 at 10:13 PM
$QLGN I’ve been in this turd back in 2020 and I was swing trading it. I won some, I lost some, but what I’ve seen overall is that this turd has been on a downward spiral before it was QLGN and it was RTTR. Get dafuq out unless you’re swinging this. Keep a share as a reminder of how a company that is betting on a golden nano cancer curing feces particle is one of the biggest scam trollings you’ve ever been a part of
1 · Reply
SpacemanAlerts
SpacemanAlerts Jul. 28 at 9:28 PM
$QLGN interesting news
0 · Reply
SpacemanAlerts
SpacemanAlerts Jul. 28 at 9:25 PM
$QLGN more news
0 · Reply
sn0wball
sn0wball Jul. 28 at 5:02 PM
$QLGN Qualigen Therapeutics Announces $4.5 Million Private Placement of Series A-3 Convertible Preferred Stock July 28, 2025 12:41 ET | Source: Qualigen Therapeutics, Inc.
0 · Reply
BillyMcgraw
BillyMcgraw Jul. 28 at 5:02 PM
$CHPT $QLGN two worst holds of my life glad to never touch these stocks again.
1 · Reply
Pillemann1
Pillemann1 Jul. 28 at 4:58 PM
$QLGN Qualigen Therapeutics, Inc Investor Relations Alert News Alert for Qualigen Therapeutics Inc. (QLGN). Qualigen Therapeutics Announces $4.5 Million Private Placement of Series A-3 Convertible Preferred Stock
0 · Reply
SpacemanAlerts
SpacemanAlerts Jul. 28 at 4:57 PM
$QLGN whats the news?
0 · Reply
The_Gambl3r
The_Gambl3r Jul. 28 at 4:45 PM
$QLGN 👀
0 · Reply
YungnredE
YungnredE Jul. 25 at 3:11 PM
$QLGN Wow this is a very horrible scam stock. Will be in my scam watchlist. Won't trust any news they come out with
1 · Reply
Jackie_Treehorn
Jackie_Treehorn Jul. 24 at 10:00 PM
$QLGN how is this still listed? 🤣
0 · Reply